Occident Group

11/2020 team

WELCOME MIRCO

OCCIDENT welcomes Mirco Müller as new Investment Analyst for the life sciences sector at the Zug office. Mirco studied chemistry and economics at the University of Freiburg in Germany and spent a semester abroad in Singapore. He gained professional experience in the research and development of novel material systems. At OCCIDENT, Mirco supports the comprehensive analysis and due diligence of new investment opportunities.

11/2020 About

OCCIDENT IN THE VENTURE CAPITAL MAGAZINE

“Strong companies are shaped by entrepreneurs and not by investors”, our CEO Patrizia Schützenhöfer is quoted in the special edition Start-up 2021 of Venture Capital Magazine. Which manifold added value investors can bring into start-ups besides capital and how valuable a good fit in a consortium is, gets explained in the corresponding article.

Issue 07/2020 from page 40 (only available in German language)

10/2020 Portfolio

FOLLOW-UP INVESTMENT IN ADIVO

adivo, our portfolio company in the field of veterinary medicine, convinced us for a second time to invest in the promising technology and the highly motivated team together with High-Tech Gründerfonds. The current funding will be used to continue the company’s own projects, expand the successful partnering and enlarge the team.

More about adivo

09/2020 About

OCCIDENT FEATURED IN THE PLATTFORM LIFE SCIENCES

We definitely “dare” – with almost 50% of our life sciences investments in the biotech sector, we are absolutely convinced of its success potential, innovative strength and impact. How our CEO, Patrizia Schützenhöfer, assesses the current situation of venture capital in biotech and how OCCIDENT invests in this field, can be found in the latest issue of the Plattform Life Sciences.

Issue 03/2020 from page 134 (only available in German language)

09/2020 About

OCCIDENT INVESTS IN DEEP TECH

As a deep tech investor, we are pleased to be perceived as such by the University of Zurich. OCCIDENT is one of the most active investors in life sciences spin-offs from Swiss universities, which account for almost one third of our portfolio. Together with our German spin-offs, almost two thirds of our start-ups’ technologies were developed at universities or research institutions. For us, this once again demonstrates the great potential of excellent research in Switzerland and Germany.

TOP 100 SWISS STARTUP AWARD 2020

Just like in 2019, we congratulate three of our portfolio companies on their placements among this year’s TOP 100 Swiss Startup Award – two of them even made it into the TOP 8. Congratulations to Versantis, Resistell and hemotune for their ranking as 3 of the most promising start-ups in Switzerland. OCCIDENT is proud to have these aspiring start-ups in its portfolio.

More about Versantis

More about Resistell

More about hemotune

09/2020 About

NEW ADDRESS IN MUNICH

Growth needs space – that’s why we are moving with our Munich team into our own and bigger offices near the Gärtnerplatz. We are very much looking forward to welcoming our portfolio companies, further team members and business partners and to meeting highly motivated founders in the Isarvorstadt.

08/2020 team

WELCOME SIMON

OCCIDENT welcomes Simon Schild von Spannenberg as new Junior Investment Manager for the high-tech sector at the Munich office. Simon studied Industrial Engineering (Mechanical Engineering) as well as Energy Science and Engineering at the Technical University of Darmstadt and spent a semester abroad in Nicaragua. Afterwards he gained experience as a founder and in the field of M&A with a focus on Cleantech. At OCCIDENT, Simon is responsible for deal sourcing and building a high-tech start-up portfolio.

08/2020 Portfolio

INVESTMENT IN HEMOTUNE

For the third month in a row, we are proud to welcome a new venture to our portfolio. OCCIDENT acted as lead investor for the Series A of the Swiss start-up hemotune, which developed HemoSystem, a groundbreaking platform technology for extracorporeal blood purification. This technology uses magnetic nanoparticles to purify the blood of previously inaccessible pathogenic biomolecules and toxins. The primary applications are sepsis and septic shock, the consequences of which up to 6 million people die every year according to the WHO.

More information can be found in the press release under the following link.

More about hemotune

07/2020 Portfolio

INVESTMENT IN TUBULIS

OCCIDENT participates in the Series A financing round of the Munich-based start-up Tubulis, which is working on one of the best current innovations for improved cancer treatment. Using proprietary platform technologies, Tubulis develops uniquely tailored Antibody Drug Conjugates (ADCs) with the aim of improving and expanding their therapeutic potential. The conjugates consist of chemotherapeutic agents that are firmly bound to a cancer-sensitive antibody which enables a specific release of the drug molecule at the tumor site. Tubulis is thus developing the basis for a more targeted and effective therapy of cancer.

More information can be found in the press release under the following link.

More about Tubulis

07/2020 Portfolio

Resistell receives EIC Accelerator Grant

In times of COVID-19, the signs are more in favor of saving than investing. Especially life sciences start-ups can therefore only develop or test their life-saving technologies at a slower pace. This makes it all the more important for us to support young companies in the current situation. We are therefore very pleased that the European Commission has the same ambition and supports Resistell in the generation of an improved method for detecting antibiotic resistance with the Enhanced European Innovation Council (EIC) Accelerator Grant totaling 2.5 million euros.

More information can be found in the press release under the following link.

More about Resistell

06/2020 Portfolio

INVESTMENT IN CODE INTELLIGENCE

OCCIDENT invests in the Bonn-based start-up Code Intelligence. Together with LBBW Venture Capital und investiere, a very good consortium has been formed for the Pre-Series A financing round. Code Intelligence enables software security testing through innovative fuzzing already in the development phase of software. Using CI Fuzz, vulnerabilities can be detected earlier and fully automatically, allowing developers to analyze errors faster and to fix them at the code base. Thus CI Fuzz drastically improves the stability and reliability of software.

More information can be found in the press release under the following link.

More about Code Intelligence

06/2020 Ventures

FOLLOW-UP INVESTMENT IN ADVANCECOR

For the second time, OCCIDENT is participating in a financing round for the Munich-based biotech company advanceCOR GmbH, which specializes in the personalized therapy of cardiovascular diseases. The unique feature is the lead project Revacept® developed by advanceCOR, which does not interfere with the body’s own blood coagulation, but acts directly at the site of vascular damage. The active ingredient has already been successfully tested in two clinical trials. With the new investment, advanceCOR now wants to further accelerate the development of Revacept®.

For more information please read the press release under the following link.

More about advanceCOR

05/2020 Portfolio

GNA RECEIVES FUNDING FOR CORONA TEST

Again we have great news from our portfolio company GNA Biosolutions. The Innovative Medicines Initiative (IMI), a partnership between the European Union and the European pharmaceutical industry, has committed financial support to GNA to promote approaches to the diagnosis and treatment of COVID-19.

The IMI selected GNA as one of eight institutions and the only German lead company out of 144 proposals. The decision is based on the quality and speed in which patients can be tested for COVID-19 thanks to the disruptive technology. Due to GNA’s molecular diagnostic method using PCA, patients could be tested almost anywhere in laboratory quality and within 15 to 20 minutes they would have clarity if they were suffering from corona virus.

For more information please see an article by AktienCheck (link in German language) and the press release of IMI (Link).

More about GNA

04/2020 Portfolio

GNA has developed corona test

Our Munich-based portfolio company GNA Biosolutions is making its contribution to the fight against the corona virus and is also supported by the Bavarian Ministry of Economic Affairs in order to enable the market launch of the mobile test device within 8-12 weeks. GNA Biosolutions uses a novel detection method, which provides a reliable result regarding a possible COVID-19 disease within 15 minutes. With 1,000 devices about 300,000 tests could be performed daily.

In addition to the current challenges, the rapid diagnosis of highly infectious diseases will continue to provide a good database for the future in order to identify pandemic risks at an early stage and initiate appropriate measures.

More information can be found in the article in Süddeutsche Zeitung (text in German language) under the following link.

More about GNA

03/2020 About

OCCIDENT – digital and financially strong

As a company that has been digital for years, the conversion to home office in the course of COVID-19 was not difficult for us. Since mid-March, we have been keeping our physical distance responsibly and considerately, but we are still making a digital effort to promote interpersonal exchange and cohesion during the crisis. During this time, it becomes particularly clear how important the digitalization of our processes and the solidarity towards our fellow human beings are.

For years, OCCIDENT has been investing in start-ups that make digital and medical progress possible and thus represent added value for society. As a financially strong and entrepreneurial investor, we will continue to support start-ups. Especially in the current crisis, we take our responsibility seriously and continue to be a trustworthy partner for visionary founders.

Stay healthy and take care of yourself!

01/2020 Portfolio

Follow-up Investment in Lunaphore

Already for the third time, OCCIDENT participates in a financing round for the Swiss diagnostics company Lunaphore, which revolutionizes tumor diagnostics with its technology. Following the successful market launch of LabSat, the new funds will flow into the company’s growth and internationalization, as well as into new innovations.

More information can be found in the press release under the following link.

More about Lunaphore

01/2020 Portfolio

News advanceCOR

Congratulations to advanceCOR! With its lead compound Revacept®, our portfolio company was able to prevent the local activation of blood platelets at sites of vascular injury in carotid stenosis patients in a phase II clinical trial and thereby achieving an almost 50% reduction in new silent strokes (microinfarctions). More information can be found in the press release under the following link.

More about advanceCOR

01/2020 EXIT

Successful exit Cunesoft

We are happy to start the new year with great news. After nearly four years of investing in Cunesoft and supporting the exciting development of digital data management in the healthcare sector, we could realize a successful exit. With Phlexglobal, Cunesoft has found a perfect match for its further internationalization of its unique software solution. We congratulate the founders and the whole team and wish them all the best!

More information can be found in the press release under the following link.

01/2020 About

We are climate neutral

Also at the beginning of the year 2020, climate change and its negative consequences are more present than ever. As a sustainable company, this issue is important to us, which is why we also want to make our contribution to climate protection. We have calculated our CO2 corporate balance for the year 2019 and, based on this, support projects to reduce carbon dioxide emissions in cooperation with the Swiss foundation myclimate.

More about myclimate

12/2019 About

When you raise your eyes, you see no boundaries

(Japanese proverb)

We would like to make ourselves aware at the end of the year that in a fast-moving and continuously success-oriented time it is always necessary to pause for a moment in order to actually be able to realize the unlimited potential of innovation.

With this in mind, we would like to thank you for the enriching and inspiring cooperation and look forward to working together in the future to raise our eyes and improve tomorrow‘s life sustainably through meaningful investments.

We wish you a peaceful, inspiring Christmas season and a fantastic year in 2020.

12/2019 Portfolio

Follow-on Investment in Resistell

Resistell closes the year successfully with OCCIDENT as lead investor in the Series A financing round. Founded in 2018, the start-up is dedicated to the precise and rapid identification of antibiotic resistance. In order to advance clinical validation and marketing approval, additional funding was provided by existing and new investors. More information can be found in the press release under the following link.

More about Resistell

12/2019 Portfolio

Investment in Algiax Pharmaceuticals

OCCIDENT invests in the German clinical-stage biotech start-up Algiax Pharmaceuticals, which develops innovative and unique therapeutics for the treatment of neuropathic pain. More information can be found in the press release under the following link.

More about Algiax

12/2019 events

BioM BioAngels Pitch Day in Munich

Congratulations to BioM for the successful 7th BioAngels Pitch Day in Munich! With the excellent selection of startups BioM proved the exceptional quality of the event again this year. We were happy to support as sponsor and investor expert and are looking forward to the events in the new year.

More about BioM

10/2019 Human Resources

OCCIDENT Workshop in Hamburg

Investing in start-ups is based on mutual trust and good cooperation. Our investment team has grown this year, and so we took the time to professionalize the topic of communication in a workshop in Hamburg. In addition to talking about our own motivation and inspiration for our job, we also had time to get to know each other better away from our everyday work.

09/2019 About

First OCCIDENT Event in Germany

For the start of autumn and on the occasion of OCCIDENT’s new office in Munich we invited to a housewarming. In a relaxed atmosphere, our portfolio companies, existing and potential co-investors as well as business partners were able to engage in fruitful exchanges. Interesting conversations, exciting discussions and promising contacts made the evening a full success. We thank all guests for the great premiere and look forward to further inspiring events.

09/2019 Portfolio

TOP 100 Swiss Start-Up Award 2019

Congratulations to our portfolio companies Lunaphore, Versantis and Resistell on their respective placements among the 35 most promising start-ups in Switzerland! We were pleased to support the award organized by Venturelab as a jury member and are looking forward to further successful cooperation.

More about Lunaphore

More about Versantis

More about Resistell

08/2019 Human Resources

Offsite Team Meeting in Munich

In August we spent our offsite in Munich. As a team, we were able to deepen our knowledge in the areas of life sciences and digital with exciting topics in the Deutsches Museum, as well as gain exclusive insight behind the scenes of two of our portfolio companies. A Segway tour through the city, the numerous culinary highlights and a visit to OCCIDENT’s new offices rounded off the positive impression of Munich and increased the anticipation of further exciting investments.

08/2019 Portfolio

Investment in GNA Biosolutions

OCCIDENT invests in the German molecular diagnostics company GNA Biosolutions, which is developing a disruptive technology for ultrafast and cost-effective molecular diagnostic analysis of DNA from complex clinical samples. More information can be found in the press release under the following link.

More about GNA

08/2019 About

Munich Office

OCCIDENT has moved into new offices at Mindspace Stachus in Munich. We are looking forward to the new location, the local exchange and the proximity to our current and future portfolio companies.

07/2019 Portfolio

News InSphero

Congratulations to InSphero! Our portflio company has achieved a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

More

05/2019 Portfolio

News iThera

Our portfolio company iThera Medical received the CE Mark for its MSOT Acuity imaging system. This non-invasive, novel technology enables soft tissue imaging without the use of radiation or contrast agents. It combines laser excitation and ultrasound detection for the analysis of hemoglobin, lipids, collagen and other chromophores in tissue. Congratulations!

More

05/2019 About

Occident featured in the VC Magazin

Many thanks to the German VentureCapital Magazin for the presentation of OCCIDENT in the current issue. We are delighted to have been able to contribute our experience to the cover story and to share our fascination for ventures.

Issue 05/2019 from page 18 (only available in German language)

04/2019 Portfolio

News Resistell

Resistell has attracted CNN Money’s attention with its innovative approach to fighting antibiotic resistance. In her 90-second interview, founder Danuta Cichocka provides exciting insights into her company.

Video to LinkedIn

04/2019 Portfolio

News adivo

adivo signs first major collaboration agreement with Bayer Animal Health to jointly develop species-specific therapeutic monoclonal antibodies to address the demand for innovative pet therapies. We congratulate adivo on this major step and look forward to further successful collaborations.

More

03/2019 Portfolio

News Implandata

Congratulations to our portfolio company Implandata Ophthalmic Products on the CE certification of the EYEMATE-IO 1.1 microsensor implant for continuous monitoring of intraocular pressure in glaucoma patients! Market entry can thus take place in April 2019.

More

03/2019 Portfolio

News Resistell

According to the Swiss business magazine Bilan, our portfolio company Resistell is one of the 50 start-ups in which to invest in 2019. We agree and congratulate Resistell!

More about Resistell

02/2019 About

Fostering talents

OCCIDENT is the proud partner of the Co-Operaid Talents Program and this year again supports 25 disadvantaged students in Laos, Cambodia and Bangladesh with scholarships. This enables these young, highly motivated people to make their dreams come true and to create sustainable added value for the society, often disadvantaged ethnic minorities of the respective country, through their education.

In 2018, the Talents Program produced the first graduate, a lawyer from Bangladesh.

More about the Co-Operaid Talents program

02/2019 About

Tomorrow happens in Germany

In recent years, OCCIDENT has intensified its investment activities in Germany and we are now ready to take the next step by establishing our own branch office in Munich. We believe that Munich is a great location for our business, thanks to its top international universities and global technology leaders, along with a solid network of renowned investors.

Our goal is clear: we will press on and deepen our existing investment strategy in Germany, by reinforcing and expanding our investment team there as well.

02/2019 Portfolio

News Lunaphore

Congratulations to our portfolio company Lunaphore for the launch of its first product LabSat™ for research applications!

More

12/2018 Human Resources

Team-Offsite Meeting in Heidelberg

At the end of the year, the OCCIDENT Team visited the German university city of Heidelberg. An exact picture of the human anatomy could be attained in the Körperwelten Museum which led to conversations about the one or the other portfolio company. The Christmas market in the picturesque old town of Heidelberg provided a very contemplative setting for Christmas.

With this in mind, we wish you a peaceful and Inspiring Christmas season!

12/2018 Portfolio

News advanceCOR

The OCCIDENT portfolio company advanceCOR announces the successful completion of patient recruitment for the phase II study of Revacept in patients with symptomatic carotid artery stenosis. Congratulations on reaching this important milestone!

More

12/2018 Portfolio

Investment in iThera Medical

OCCIDENT invests in the Munich-based diagnostics company iThera Medical together with existing investors Fluxunit – Osram Ventures, Bayern Kapital, BayBG Bayrische Beteiligungsgesellschaft and Extorel in its extended Series C financing round of 9 million euros. The company develops imaging methods for medical diagnostics based on multispectral optoacoustic tomography (MSOT). This laser-enabled technology allows for the evaluation of optical tissue properties and thus enables a more accurate and non-invasive diagnosis in a variety of indications such as cancer and inflammatory diseases. The additional funding will be used for the further development of the MSOT systems and for entry into the clinical market.

More about iThera Medical

12/2018 Portfolio

News Cunesoft

Gruenderszene.de published a good article (only available in German language) about our portfolio company Cunesoft and its use of artificial intelligence as added value for the pharmaceutical industry (link).

12/2018 Portfolio

Investment in Resistell

OCCIDENT invests in the Basel based diagnostic startup Resistell, which develops a technology for more precise and fast antibiotic susceptibility testing. More information in the press release under the following link.

More about Resistell

12/2018 Portfolio

News Implandata

In a clinical study, the EYEMATE-SC sensor was implanted in the human eye for the first time. Congratulations on reaching this important milestone!

More

11/2018 Portfolio

News Lunaphore

Lunaphore starts strategic partnership with A. Menarini Diagnostics S.r.l., one of Europe’s leading diagnostic solution providers and part of the Menarini Group, bringing a new and innovative system to the market.

More

10/2018 About

Happy to support

Technology fascinates us, but in this case the challenge is simplicity and robustness. As part of our philanthropic activities, we are pleased to support the aid organisation Aqua Alimenta and its irrigation technology as the key to food security for smallholder families in Odisha, India.

More about Aqua Alimenta

More about Projekt Odisha

09/2018 Portfolio

News Lunaphore

Lunaphore starts strategic partnership with A. Menarini Diagnostics S.r.l., one of Europe’s leading diagnostic solution providers and part of the Menarini Group, bringing a new and innovative system to the market.

More

09/2018 Human Resources

Offsite Team Meeting in Montafon

A trip to the Austrian Alps allowed the OCCIDENT team to work on further improving cooperation and internal processes. Despite bad weather, there were also plenty of opportunities to get to know each other better off the job.

09/2018 Portfolio

TOP 100 Swiss Startups 2018

Congratulaitons to Lunaphore and Versantis! We are proud that two of our portfolio companies have been voted amongst the top 10 startups in Switzerland.

More about Lunaphore

More about Versantis

09/2018 Portfolio

News 4tiitoo

Controlling the computer with your eyes – this fascinating technology has also made the Frankfurter Allgemeine curious. The complete article can be found under the following the link (German language).

Or as aptly drafted by VDI, the engineers’ news portal: “PC reads wishes from the eyes” (article in German language under the following link)

08/2018 Portfolio

Follow-on Investment in Lunaphore

OCCIDENT participates in the financing round of the Swiss medtech firm Lunaphore that develops innovative next-generation devices for cancer tissue diagnostics. The funds will enable the product’s CE marking and support product launch. More information in the press release under the following link.

08/2018 Portfolio

Follow-on investment in iMusician

iMusician has shown in recent years that its business model can also be successful internationally. In order to promote further internationalization, iMusician closes another financing round with OCCIDENT as lead investor and other investors.

More about iMusician

08/2018 Portfolio

Investment in adivo

OCCIDENT invests in the Munich-based biotech company adivo, which develops therapeutic antibodies for pets. More information in the press release under the following link.

More about adivo

06/2018 Portfolio

News InSphero

InSphero starts promising collaboration with ALPCO on further development of its product range in the area of diabetes research.

More

06/2018 Human Resources

Team Offsite: Mastering challenges together

At AdventureRooms Zurich, the team worked under pressure to explore all the options for escaping from a locked room. Fantastic cooperation in the team and the different skills of each individual team member made this experience a great success. As a reward, there were culinary delights to enjoy at Food Zurich.

06/2018 Portfolio

News Lunaphore

Lunaphore launches a cooperation with Spanish company Vitro S.A. in the field of In Situ Hybridization (ISH).

More

05/2018 Portfolio

Investment in Implandata Ophthalmic Products

OCCIDENT participates in the medical device company Implandata Ophthalmic Products in Hannover. More information in the press release under the following link.

More about Implandata

04/2018 Portfolio

Follow-on investment in InSphero

To support the rapid development of InSphero as the leading supplier of 3D microtissues, OCCIDENT joined forces with new and existing investors to provide follow-on financing for this Zurich-based biotech firm. This will allow InSphero to reinforce its outstanding position in this fast-growing future market.

More about InSphero

04/2018 Portfolio

Follow-on financing for 4tiitoo

Thanks to the intense interest from industry and full order books, 4tiitoo decided to raise additional capital to realize its full potential. After strengthening the team with a VP Sales, the company is now ideally positioned to revolutionize the workplace with intuitive gaze-tracking technology.

03/2018 Portfolio

News Lunaphore

OCCIDENT’S portfolio company Lunaphore is launching a promising collaboration with Perkin Elmer for the quicker analysis of tumor samples.

More

03/2018 team

New Junior Legal Counsel

OCCIDENT is pleased to welcome Matthias Schrader to the team. Following completion of law school in Lucerne and admission to the Swiss bar, Matthias is taking on the position of Junior Legal Counsel in the OCCIDENT team, with responsibility for all legal matters.

03/2018 Portfolio

Investment in advanceCOR

The Munich-based biotech firm advanceCOR develops innovative medications for the personalized treatment of cardiovascular diseases. Financing was realized with a group of reputable co-investors and provides advanceCOR with liquidity until completion of the phase II studies on patients.

More about advanceCOR

02/2018 Portfolio

News Versantis

The following article focuses on Vincent Forster, CEO & Co-Founder of our portfolio company Versantis.

02/2018 Human Resources

Offsite team meeting with Asian culinary delights

After an introduction to traditional sake making and Japanese drinking culture, the OCCIDENT team enjoyed a sake tasting. Dinner afterwards was a great occasion to explore and enjoy the diverse cuisine of Indonesia.

INVESTING ON THE EDGE OF SCIENCE

ADIVO CONCLUDES FURTHER GLOBAL COLLABORATION AGREEMENT

CODE INTELLIGENCE'S FUZZ TESTING IS OPEN SOURCE

WELCOME LISA

WE ARE ONCE AGAIN CLIMATE NEUTRAL

WELCOME AAGAM

GNA RECEIVES AUTHORIZATION

LET'S SHOW INITIATIVE!

SWISS TECHNOLOGY AWARD FOR HEMOTUNE

WELCOME MIRCO

OCCIDENT IN THE VENTURE CAPITAL MAGAZINE

FOLLOW-UP INVESTMENT IN ADIVO

OCCIDENT FEATURED IN THE PLATTFORM LIFE SCIENCES

OCCIDENT INVESTS IN DEEP TECH

TOP 100 SWISS STARTUP AWARD 2020

NEW ADDRESS IN MUNICH

WELCOME SIMON

INVESTMENT IN HEMOTUNE

INVESTMENT IN TUBULIS

Resistell receives EIC Accelerator Grant

INVESTMENT IN CODE INTELLIGENCE

FOLLOW-UP INVESTMENT IN ADVANCECOR

GNA RECEIVES FUNDING FOR CORONA TEST

GNA has developed corona test

OCCIDENT – digital and financially strong

Follow-up Investment in Lunaphore

News advanceCOR

Successful exit Cunesoft

We are climate neutral

When you raise your eyes, you see no boundaries

Follow-on Investment in Resistell

Investment in Algiax Pharmaceuticals

BioM BioAngels Pitch Day in Munich

OCCIDENT Workshop in Hamburg

First OCCIDENT Event in Germany

TOP 100 Swiss Start-Up Award 2019

Offsite Team Meeting in Munich

Investment in GNA Biosolutions

Munich Office

News InSphero

News iThera

Occident featured in the VC Magazin

News Resistell

News adivo

News Implandata

News Resistell

Fostering talents

Tomorrow happens in Germany

News Lunaphore

Team-Offsite Meeting in Heidelberg

News advanceCOR

Investment in iThera Medical

News Cunesoft

Investment in Resistell

News Implandata

News Lunaphore

Happy to support

News Lunaphore

Offsite Team Meeting in Montafon

TOP 100 Swiss Startups 2018

News 4tiitoo

Follow-on Investment in Lunaphore

Follow-on investment in iMusician

Investment in adivo

News InSphero

Team Offsite: Mastering challenges together

News Lunaphore

Investment in Implandata Ophthalmic Products

Follow-on investment in InSphero

Follow-on financing for 4tiitoo

News Lunaphore

New Junior Legal Counsel

Investment in advanceCOR

News Versantis

Offsite team meeting with Asian culinary delights